BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

832 related articles for article (PubMed ID: 30061088)

  • 21. Indirect Treatment Comparisons of Ibrutinib Versus Physician's Choice and Idelalisib Plus Ofatumumab in Patients With Previously Treated Chronic Lymphocytic Leukemia.
    Sorensen S; Wildgust M; Sengupta N; Trambitas C; Diels J; van Sanden S; Xu Y; Dorman E
    Clin Ther; 2017 Jan; 39(1):178-189.e5. PubMed ID: 28062113
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Safety and activity of BTK inhibitor ibrutinib combined with ofatumumab in chronic lymphocytic leukemia: a phase 1b/2 study.
    Jaglowski SM; Jones JA; Nagar V; Flynn JM; Andritsos LA; Maddocks KJ; Woyach JA; Blum KA; Grever MR; Smucker K; Ruppert AS; Heerema NA; Lozanski G; Stefanos M; Munneke B; West JS; Neuenburg JK; James DF; Hall N; Johnson AJ; Byrd JC
    Blood; 2015 Aug; 126(7):842-50. PubMed ID: 26116658
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Ibrutinib in Advanced Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma: Lower Risk of Hepatitis B Virus Reactivation.
    Yang S; Zhu R; Li N; Feng Y; Zuo R; Gale RP; Huang X
    Acta Haematol; 2022; 145(1):54-62. PubMed ID: 34569486
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Extended Treatment with Single-Agent Ibrutinib at the 420 mg Dose Leads to Durable Responses in Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma.
    Coutré SE; Furman RR; Flinn IW; Burger JA; Blum K; Sharman J; Jones J; Wierda W; Zhao W; Heerema NA; Johnson AJ; Tran A; Zhou C; Bilotti E; James DF; Byrd JC; O'Brien S
    Clin Cancer Res; 2017 Mar; 23(5):1149-1155. PubMed ID: 28073846
    [No Abstract]   [Full Text] [Related]  

  • 25. Ibrutinib for the treatment of chronic lymphocytic leukemia and mantle cell lymphoma.
    McDermott J; Jimeno A
    Drugs Today (Barc); 2014 Apr; 50(4):291-300. PubMed ID: 24918646
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Phase I study of ibrutinib in Japanese patients with treatment-naïve chronic lymphocytic leukemia/small lymphocytic lymphoma.
    Shibayama H; Teshima T; Choi I; Hatake K; Sekiguchi N; Yoshinari N
    J Clin Exp Hematop; 2019; 59(4):179-186. PubMed ID: 31866619
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Managing Ibrutinib-Intolerant Patients With B-Cell Malignancies.
    Muñoz J; Sarosiek S; Castillo JJ
    Oncologist; 2023 Apr; 28(4):309-318. PubMed ID: 36723874
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Development of the Bruton's tyrosine kinase inhibitor ibrutinib for B cell malignancies.
    Gayko U; Fung M; Clow F; Sun S; Faust E; Price S; James D; Doyle M; Bari S; Zhuang SH
    Ann N Y Acad Sci; 2015 Nov; 1358():82-94. PubMed ID: 26348626
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Ibrutinib in CLL/SLL: From bench to bedside (Review).
    Zi F; Yu L; Shi Q; Tang A; Cheng J
    Oncol Rep; 2019 Dec; 42(6):2213-2227. PubMed ID: 31638169
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Indirect comparisons of efficacy of zanubrutinib versus orelabrutinib in patients with relapsed or refractory chronic lymphocytic leukemia/small lymphocytic lymphoma or relapsed or refractory mantle cell lymphoma.
    Song Y; Zhou K; Yang S; Hu J; Zou D; Gao S; Pan L; Wang T; Yang H; Zhang H; Zhou D; Ji J; Xu W; Feng R; Jin J; Lv F; Huang H; Fan X; Xu S; Zhu J
    Invest New Drugs; 2023 Aug; 41(4):606-616. PubMed ID: 37420136
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Ibrutinib restores immune cell numbers and function in first-line and relapsed/refractory chronic lymphocytic leukemia.
    Solman IG; Blum LK; Hoh HY; Kipps TJ; Burger JA; Barrientos JC; O'Brien S; Mulligan SP; Kay NE; Hillmen P; Byrd JC; Lal ID; Dean JP; Mongan A
    Leuk Res; 2020 Oct; 97():106432. PubMed ID: 32911375
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A phase 1 trial of ibrutinib plus palbociclib in previously treated mantle cell lymphoma.
    Martin P; Bartlett NL; Blum KA; Park S; Maddocks K; Ruan J; Ridling L; Dittus C; Chen Z; Huang X; Inghirami G; DiLiberto M; Chen-Kiang S; Leonard JP
    Blood; 2019 Mar; 133(11):1201-1204. PubMed ID: 30692121
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Safety and efficacy of dual PI3K-δ, γ inhibitor, duvelisib in patients with relapsed or refractory lymphoid neoplasms: A systematic review and meta-analysis of prospective clinical trials.
    Wang Z; Zhou H; Xu J; Wang J; Niu T
    Front Immunol; 2022; 13():1070660. PubMed ID: 36685572
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Sustained efficacy and detailed clinical follow-up of first-line ibrutinib treatment in older patients with chronic lymphocytic leukemia: extended phase 3 results from RESONATE-2.
    Barr PM; Robak T; Owen C; Tedeschi A; Bairey O; Bartlett NL; Burger JA; Hillmen P; Coutre S; Devereux S; Grosicki S; McCarthy H; Li J; Simpson D; Offner F; Moreno C; Zhou C; Styles L; James D; Kipps TJ; Ghia P
    Haematologica; 2018 Sep; 103(9):1502-1510. PubMed ID: 29880603
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Current Status of Bruton's Tyrosine Kinase Inhibitor Development and Use in B-Cell Malignancies.
    Aw A; Brown JR
    Drugs Aging; 2017 Jul; 34(7):509-527. PubMed ID: 28536906
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Ibrutinib, lenalidomide, and rituximab in relapsed or refractory mantle cell lymphoma (PHILEMON): a multicentre, open-label, single-arm, phase 2 trial.
    Jerkeman M; Eskelund CW; Hutchings M; Räty R; Wader KF; Laurell A; Toldbod H; Pedersen LB; Niemann CU; Dahl C; Kuitunen H; Geisler CH; Grønbæk K; Kolstad A
    Lancet Haematol; 2018 Mar; 5(3):e109-e116. PubMed ID: 29396091
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Efficacy and Safety of Ibrutinib in Indian Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia and Mantle Cell Lymphoma: Cases from a Named Patient Program.
    Agarwal MB; Bhurani D; Shah C; Sood N; Singhal M; Kamat A; Chezhian S; Mishra S; Nagrale D
    Indian J Med Paediatr Oncol; 2017; 38(4):508-515. PubMed ID: 29333021
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Treatment patterns, adverse events, healthcare resource use and costs among commercially insured patients with mantle cell lymphoma in the United States.
    Kabadi SM; Near A; Wada K; Burudpakdee C
    Cancer Med; 2019 Dec; 8(17):7174-7185. PubMed ID: 31595715
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Descriptive analysis of dosing and outcomes for patients with ibrutinib-treated relapsed or refractory chronic lymphocytic leukemia in a Canadian centre.
    Uminski K; Brown K; Bucher O; Hibbert I; Dhaliwal DH; Johnston JB; Geirnaert M; Dawe DE; Banerji V
    Curr Oncol; 2019 Oct; 26(5):e610-e617. PubMed ID: 31708654
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Safety and activity of ibrutinib in combination with nivolumab in patients with relapsed non-Hodgkin lymphoma or chronic lymphocytic leukaemia: a phase 1/2a study.
    Younes A; Brody J; Carpio C; Lopez-Guillermo A; Ben-Yehuda D; Ferhanoglu B; Nagler A; Ozcan M; Avivi I; Bosch F; Caballero Barrigón MD; Hellmann A; Kuss B; Ma DDF; Demirkan F; Yağci M; Horowitz NA; Marlton P; Cordoba R; Wrobel T; Buglio D; Streit M; Hodkinson BP; Schaffer M; Alvarez J; Ceulemans R; Balasubramanian S; de Jong J; Wang SS; Fourneau N; Jurczak W
    Lancet Haematol; 2019 Feb; 6(2):e67-e78. PubMed ID: 30642819
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 42.